Nautilus Biotechnology
Nautilus Biotechnology develops the Voyager platform, which uses Iterative Mapping technology for accurate single-molecule quantification of proteins and proteoforms. Its products are designed for researchers in drug development, biomarker discovery, and exploratory biology to provide comprehensive views of the proteome and support deep biological insights. The organization aims to revolutionize biomedicine by unlocking the complexity of the proteome to positively impact global health.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2016
- Employees
- 148
- Stage
- Public
- Members see funding amounts. .
- Founders
- Sujal Patel, Parag Mallick, PhD
Is this your organization? Claim it
Madrona at 30: Sujal Patel on What Real VC Support Looks Like in a Crisis
When Isilon's stock fell to $1.83, Sujal Patel was stepping back into the CEO chair of a public company that was falling apart. What Madrona did in that moment is what he still talks about over a decade later. Sujal Patel founded Isilon Systems at 26 and built it into a storage infrastructure leader — but the path wasn't straight. Sujal reflects on the Isilon turnaround: the financial crisis, the layoff, the board dynamics, and how the company eventually reached $100M quarters before selling. He also shares what he's carried from that experience into his current work at Nautilus Biotechnology…
Madrona at 30 Years Interview Spotlight: Sujal Patel
Serial founder Sujal Patel, Co-Founder & CEO, Nautilus Biotechnology, reflects on his early partnership with Madrona during the creation of Isilon and how the firm supported him through challenges and turnarounds. He highlights the unique network effects that Madrona helps spark: founders building companies and then their own employees going on to found new ones. Sujal also points out to GeekWire’s John Cook Madrona’s deep civic engagement and why the firm still carries that “entrepreneurial spark” that sets it apart as it looks to the future.
Nautilus CEO Sujal Patel Delays Biotech Product Launch to Late 2026, Lays Off 16% Workforce Amid Strategic Shift
Nautilus Biotechnology laid off 16% of its workforce and delayed its product launch to late 2026 to pursue a higher-performance proteomics platform. CEO Sujal Patel emphasized the company’s strong financial position with over $206 million in cash despite the stock price drop.
By Nautilus Biotechnology
Nautilus to Receive Up to $6M from ARPA-H SEEDS Consortium to Measure Proteoforms Driving Alzheimer’s and Ewing Sarcoma
Nautilus joins the ARPA-H-funded SEEDS consortium and expects up to $6 million to deploy its Voyager platform to measure proteoforms linked to Alzheimer’s disease and Ewing sarcoma, supporting a $51.7 million, four-year effort to predict misfolding of intrinsically disordered proteins and enable earlier detection and intervention. The consortium is co-led by the Buck Institute and Georgetown University and will combine protein science, AI, and computational approaches to study disease-causing protein behavior.
People
See all 4-
Sujal Patel Executive Officer, Director, Founder & CEO
-
Parag Mallick Founder & Chief Scientist
-
Anna Mowry Executive, Chief Financial Officer
Online
Questions about Nautilus Biotechnology
What is Nautilus Biotechnology?
Nautilus Biotechnology is a public company based in Seattle that develops the Voyager platform for single-molecule quantification of proteins and proteoforms.
What is Nautilus Biotechnology known for?
Nautilus Biotechnology is known for Iterative Mapping technology and proteome analysis tools designed for drug development, biomarker discovery, and exploratory biology.
What has Nautilus Biotechnology been in the news for?
GeekWire reported in February 2025 that Nautilus Biotechnology CEO Sujal Patel delayed the company's biotech product launch to late 2026 and announced layoffs amid a strategic shift.
Who are the people behind Nautilus Biotechnology?
Sujal Patel is founder, CEO, executive officer and director at Nautilus Biotechnology, and Parag Mallick is founder and chief scientist. Anna Mowry is chief financial officer, and Ken Suzuki is chief marketing officer.
Who invested in Nautilus Biotechnology, and how much has it raised?
Members of Seattle Flow see Nautilus Biotechnology's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Nautilus Biotechnology based?
Nautilus Biotechnology is based in Seattle.